Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, J?nne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024 Jun 03; 14(6):982-993.

View in: PubMed

subject areas

Acetonitriles
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Female
Humans
Male
Middle Aged
Mutation
Neoplasm Metastasis
Piperazines
Proto-Oncogene Proteins p21(ras)
Pyrimidines
Treatment Outcome

authors with profiles

Marcia Cruz-Correa

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support